These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39192830)

  • 1. Acceptability of CYLTEZO pen among biologics autoinjector patients, autoinjector Naïve patients, and healthcare professionals.
    Perez R; Suman JD; Reynolds J
    Expert Opin Drug Deliv; 2024 Aug; ():. PubMed ID: 39192830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
    Menter A
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2929-2932. PubMed ID: 37875714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
    Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Experience with the SensoReady
    Jathanakodi S; Both C; Brueckmann I; Rose L; Nasseri N; Raynauld JP; Narula N
    Patient Prefer Adherence; 2024; 18():1107-1118. PubMed ID: 38854477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey.
    Tischer B; Mehl A
    Patient Prefer Adherence; 2018; 12():1413-1424. PubMed ID: 30122906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey.
    Fenwick S; Thakur K; Munro D
    Rheumatol Ther; 2019 Jun; 6(2):195-206. PubMed ID: 30790242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V
    Rheumatol Ther; 2024 Oct; 11(5):1081-1084. PubMed ID: 39120850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.
    Bhat S; Patel M; Duly K; Choi D
    Ann Pharmacother; 2022 Dec; 56(12):1356-1364. PubMed ID: 35392668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Wins Designation as a Biosimilar Product to Humira.
    Aschenbrenner DS
    Am J Nurs; 2022 Feb; 122(2):24. PubMed ID: 35085144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF).
    Moschetti V; Buschke S; Bertulis J; Hohl K; McCabe D
    Expert Opin Biol Ther; 2024 Jul; 24(7):673-679. PubMed ID: 38739422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
    Fleischmann RM; Bock AE; Zhang W; Godfrey CM; Vranic I; Cronenberger C; Dokoupilová E
    Rheumatol Ther; 2022 Jun; 9(3):839-850. PubMed ID: 35304684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review.
    Corominas H; Young D; Cummings JRF; Bouhnik Y; Armuzzi A; Thaci D; Kim J
    Clin Drug Investig; 2023 Aug; 43(8):579-593. PubMed ID: 37615857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
    von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
    Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
    [No Abstract]   [Full Text] [Related]  

  • 14. Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review.
    Allegretti JR; Brady JH; Wicker A; Latymer M; Wells A
    Adv Ther; 2024 May; 41(5):1775-1794. PubMed ID: 38466559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.
    Kivitz A; Segurado OG
    Expert Rev Med Devices; 2007 Mar; 4(2):109-16. PubMed ID: 17359217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
    Ghil J; Zielińska A; Lee Y
    Curr Med Res Opin; 2019 Mar; 35(3):497-502. PubMed ID: 30561229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
    Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA.
    Strand V; Bender S; McCabe D
    Rheumatol Ther; 2024 Oct; 11(5):1291-1302. PubMed ID: 39120847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis.
    Schiff M; Koo J; Jin E; Schiller E; Day A; Stevens R; Laskar C
    Adv Ther; 2016 Feb; 33(2):199-213. PubMed ID: 26833303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
    BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.